CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Glenmark Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Glenmark Pharmaceuticals Ltd
B D S Marg
Chakala, Off Western Express Highway
Phone: +91 2240189999p:+91 2240189999 MUMBAI, 400099  India Ticker: GLENMARKGLENMARK
Business Summary
Glenmark Pharmaceuticals Limited is an India-based research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over the counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. The Company is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes-Yes-

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Managing Director Glenn M.Saldanha 54 1/1/2023 1/1/1998
Global Chief Financial Officer, Executive Director V. S.Mani 59 5/29/2018 11/16/2017
Compliance Officer, Company Secretary HarishKuber 3/31/2021 2/2/2017
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Glenmark Generics Ltd B-2, Mahalaxmi Chambers MUMBAI India

Business Names
Business Name
532296
GLENMARK
Glenmark Pharmaceuticals
4 additional Business Names available in full report.

General Information
Number of Employees: 14,989 (As of 3/31/2024)
Outstanding Shares: 282,188,156 (As of 9/30/2024)
Shareholders: 202,844
Stock Exchange: NSE
Fax Number: +91 2240189986


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024